Zusammenfassung
Das gemeingültige Ziel der Induktionschemotherapie ist traditionsgemäß die Senkung des Risikos einer rezidivierenden Erkrankung mit Fernmetastasen. Die Begründung einer risikoorientierten Vorgehensweise zur definitiven Lokalbehandlung wird zum Zeitpunkt der Diagnosestellung individuell geprüft (und nicht erst nach Beurteilung des Ansprechens auf die Induktionschemotherapie), um ausgewählten Patienten eine unnötige und potentiell toxische begleitende Radiochemotherapie zu ersparen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Taguchi T, Nakamura H, editors. Arterial infusion chemotherapy. Tokyo, Japan: Japanese Journal Cancer and Chemother Publishers Inc; 1994. ISBN 0385–0684.
Shiraha Y et al. Intraarterial infusion of anti-cancer drugs for malignant tumors. Diag Ther (Shindan to Chiryou). 1964;53:43.
Yoshikawa K. Chemotherapy for gastric cancer evaluation of clinical response followed by intraaortic infusion treatment. Jpn J Cancer Clin. 1973;19:776–8.
Taguchi T et al. Arterial infusion chemotherapy for advanced gastrointestinal cancer. Gastroentero Surg (Shoukaki- Geka). 1979;2:1081–8.
Nakano Y et al. Effect of intra-aortic chemotherapy on advanced gastric cancer and colorectal cancers. Jpn J Cancer Chemother. 1978;5:321–7.
Fujita F et al. Chemotherapy for the patients with nonresectable gastric cancer of Bormann type IV. Jpn J Cancer Chemother. 1977;4:1315–22.
Awane Y, Katayanagi T, Kitamura M, et al. Local intra-arterial therapy with adriamycin and 5-FU in progressive cancer. Jpn J Cancer Chemother. 1981;8:1593–9.
Taguchi T et al. Intra-arterial chemotherapy for advanced gastrointestinal cancer. Jpn J Gastroenterol Surg (Shoukaki-Geka). 1974;2:1081–8.
Kitamura M, Awane Y, Katayanagi T, et al. An evaluation of complications associated with continued intra-arterial therapy with carcinostatic drugs. Jpn J Cancer Chemother. 1980;7:1432–8.
Nakajima T et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol. 1997;4(3):203–8.
Stephens FO, Adams BG, Grea P. Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet. 1986; 162:370–4.
Aigner KR, Benthin F, Müller H. Celiac axis infusion (CA1) chemotherapy for advanced gastric cancer. In: Sugarbaker PH, editor. Management of gastric cancer. Boston: Kluwer Academic; 1991. p. 357–62.
Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.
Glinetius B, Huffmann K, Hoglund U, et al. Initial or delayed chemotherapy with best supportive. Ann Oncol. 1994;5:189–90.
Pyrhonen S, Kuitumen T, Nyandoto P, et al. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71:587–91.
Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma, Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin. JAMA. 1985; 253(14):2061–7.
Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of European Organization for Research and Treatment of Gastrointestinal Tract Co-operative Group. J Clin Oncol. 1991;9:827–31.
Kelsen D, Atiqu OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a randomized trial in gastric cancer. J Clin Oncol. 1992;10:541–8.
Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71:3813–8.
Culliman SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol. 1994;12:412–6.
Cocconi G, Bella M, Zironi S, et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1994;12(12):2687–93.
Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15: 261–7.
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
Ohtsu A, Fuse N, Yoshino T, et al. Future perspectives of chemotherapy for advanced gastric cancer. Gastric Cancer. 2009;12:60–6.
Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-FU alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol. 2007;25:LBA 4513.
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9: 215–21.
Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegaful plus mitomycin in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study, (JCOG 9205). J Clin Oncol. 2003;21:54–9.
Imamura H, Iiishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/ TOP002). Gastrointestinal cancers symposium, Orlando; 2008, abstract 5.
Jin M, Lu H, Li J, et al. Randomized three-armed phase III study of S-1 monotherapy versus S-1/CDDP versus 5-FU/ CDDP in patients with advanced gastric cancer SC-101 study. J Clin Oncol. 2008;26:221s (abstract 4533).
Boku N. JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer. Gastric Cancer. 2009; 12:43–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Taguchi, T. (2013). Magenkarzinom. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-35014-6_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35013-9
Online ISBN: 978-3-642-35014-6
eBook Packages: Medicine (German Language)